Buscar

Estamos realizando la búsqueda. Por favor, espere...

 Detalle_Publicacion

JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia

Abstract: Chronic myelogenous leukemia (CML) is a hematological malignancy that highly depends on the BCR-ABL1/STAT5 signaling pathway for cell survival. First-line treatments for CML consist of tyrosine kinase inhibitors that efficiently target BCR-ABL1 activity. However, drug resistance and intolerance are still therapeutic limitations in Ph+ cells. Therefore, the development of new anti-CML drugs that exhibit alternative mechanisms to overcome these limitations is a desirable goal. In this work, the antitumoral activity of JKST6, a naphthoquinone-pyrone hybrid, was assessed in imatinib-sensitive and imatinib-resistant human CML cells. Live-cell imaging analysis revealed JKST6 potent antiproliferative activity in 2D and 3D CML cultures. JKST6 provoked cell increase in the subG1 phase along with a reduction in the G0/G1 phase and altered the expression of key proteins involved in the control of mitosis and DNA damage. Rapid increases in Annexin V staining and activation/cleavage of caspases 8, 9 and 3 were observed after JKST6 treatment in CML cells. Of interest, JKST6 inhibited BCR-ABL1/STAT5 signaling through oncokinase downregulation that was preceded by rapid polyubiquitination. In addition, JKST6 caused a transient increase in JNK and AKT phosphorylation, whereas the phosphorylation of P38-MAPK and Src was reduced. Combinatory treatment unveiled synergistic effects between imatinib and JKST6. Notably, JKST6 maintained its antitumor efficacy in BCR-ABL1-T315I-positive cells and CML cells that overexpress BCR-ABL and even restored imatinib efficacy after a short exposure time. These findings, together with the observed low toxicity of JKST6, reveal a novel multikinase modulator that might overcome the limitations of BCR-ABL1 inhibitors in CML therapy.

 Fuente: Biomedicine & Pharmacotherapy Volume 144, December 2021, 112330

Editorial: Editions Scientifiques Elsevier

 Fecha de publicación: 01/12/2021

Nº de páginas: 17

Tipo de publicación: Artículo de Revista

 DOI: 10.1016/j.biopha.2021.112330

ISSN: 0753-3322,1950-6007

Proyecto español: SAF 2015-65113-C2-1-R ; RTI2018-094356-B-C21 ; SAF2015-65113-C2-2 ; SAF2017-88026-R

Url de la publicación: https://doi.org/10.1016/j.biopha.2021.112330

Autores/as

ARANDA-TAVÍO, HAIDÉE

RECIO, CARLOTA

MARTÍN-ACOSTA, PEDRO

GUERRA-RODRÍGUEZ, MIGUEL

BRITO-CASILLAS, YERAY

MONTERO, JUAN CARLOS

GANDULLO-SÁNCHEZ, LUCÍA

MCNAUGHTON-SMITH, GRANT

ZAPATA, JUAN MANUEL

PANDIELLA, ATANASIO

AMESTY, ÁNGEL

ESTÉVEZ-BRAUN, ANA

FERNÁNDEZ-PÉREZ, LEANDRO

GUERRA, BORJA